1. Introduction {#s0005}
===============

Measles is a highly contagious, primarily childhood, viral disease caused by a single stranded RNA paramyxovirus (genus *Morbillivirus*) [@b0005], and humans are the natural hosts of measles virus. Eighty-nine to ninety-four per cent herd immunity is required to halt measles transmission [@b0010], and in 2017, there were 173,330 reported measles cases and 109,638 estimated deaths, with a worldwide estimated measles vaccine (MV) coverage of 85% [@b0015]. This is lower than the ≥95% coverage required to eliminate measles [@b0020], and much of the World Health Organization (WHO) African Region, including the Democratic Republic of the Congo (DRC), has even lower coverage than this worldwide average [@b0025].

Measles is endemic in the DRC [@b0025]. Currently, DRC gives one routine dose of measles vaccine to children nine months of age, and in outbreak settings, to children as young as six months. Although the WHO states that all countries should include a second routine dose of MV, regardless of national routine coverage level of the first dose [@b0020], this recommendation has not been implemented in the DRC. Because coverage achieved through healthcare is low in the DRC, attempts are made to reach missed children through Supplementary Immunization Activities (SIA), which Doshi et al. found to be associated with decreased measles incidence [@b0030]. The ability of an infant to seroconvert is age-dependent due to level and decay of maternal antibodies and immunological development; regional differences in seroprevalence have been observed.

Expectant mothers in endemic areas may be more likely to have had natural measles infection, resulting in higher measles antibody levels, and so pass on higher levels of measles antibody transplacentally to their infants, resulting in longer lasting protection than would occur in expectant mothers with vaccine-induced antibody [@b0035], [@b0040]. Children in measles-endemic regions are also at risk of exposure to measles at an earlier age, and this must be considered when determining ideal age of vaccination [@b0020]. Determining drivers of seropositivity and low vaccine effectiveness (VE) is complex and can depend on immunization program logistical capacity [@b0045], vaccine potency [@b0050] and host factors, particularly immune system robustness as a function of development (age) and nutritional status [@b0055], [@b0060].

Measles has occurred even in well-vaccinated populations, raising questions of why adequate protection is not achieved in such groups [@b0065], [@b0070], [@b0075], [@b0080], [@b0085]. While vaccination induces humoral and cellular immune responses similar to those caused by natural disease, the resulting antibody levels are lower among those with vaccine - induced versus natural immunity. As measles continues to be inadequately controlled in DRC [@b0090], [@b0095], population assessment of measles immunity is needed. This study reports measles immunoglobulin G (IgG) antibody levels among children 6--59 months of age participating in the 2013--2014 Demographic and Health Survey (DHS) in the DRC, with the goal of describing population seroprotection, VE, and factors associated with decreased protection against measles.

2. Methods {#s0010}
==========

2.1. Data source and study population {#s0015}
-------------------------------------

The 2013--2014 DHS, a nationally representative survey based on a stratified two-stage cluster design, occurred from November 2013 to February 2014. The first stage of the survey consisted of Enumeration Area (EA) formation in which a stratified sample of geographic locations, or clusters (n = 540), was selected with proportional probability according to size. The second stage involved sampling households from each EA; complete listings of households were created within each cluster, and households (n = 9000) were selected with equal probability [@b0100], [@b0105], [@b0110], [@b0115]. Within the selected households, individuals interviewed included 18,827 women aged 15--49 years (all selected households) and 8656 men aged 15--59 years (50% of selected households). The DHS collected biomarker data only on children from households in which men were interviewed. In our dataset, there were 7016 children aged 6--59 months with anthropometric and measles IgG serology data available, and of these, 6706 children had data on measles infection and all other covariates of interest available (approximately 4.5% of children were missing data on covariates of interest and so were excluded from analyses).

Information was collected on weight, health outcomes, vaccination history, and vaccine-preventable disease serology. After parental consent, dried blood spots (DBS) were collected from participants to assess immunity to vaccine-preventable diseases and processed at the University of California, Los Angeles (UCLA) -- DRC laboratory at the National Laboratory for Biomedical Research (INRB) in Kinshasa. All survey data were transferred from paper questionnaires to an electronic format using the Census and Survey Processing System (U.S. Census Bureau, ICF Macro). Data were double entered and verified by comparison of both datasets.

Vaccination was reported in three ways. At the time of interview, if mothers possessed a health care worker (HCW)-provided vaccination card indicating the date the child was vaccinated for measles, this was considered a "dated card" report. These reports were only collected from children at least nine months of age, although children 9--59 months of age with a dated card report indicating vaccination at less than nine months of age were included in the "age at vaccination" analyses. If mothers possessed a vaccination card that was marked to indicate measles vaccine was administered, but lacked the date of vaccine administration, this was considered a "marked card" report. Finally, children with caregivers not presenting a card at the time of interview, yet reporting that the child had been vaccinated for measles, were grouped into the "maternal recall" report category. There were no dates associated with this type of vaccination report. Children classified as "unvaccinated" in this study were those reported as such in the 2013--2014 DHS. Additionally, among those with vaccination cards, children who had had measles (as defined by study inclusion criteria) but later received measles vaccination were then re-classified as "unvaccinated" since vaccination occurred after infection (7 children were so classified).

2.2. Laboratory analysis {#s0020}
------------------------

DBS samples were extracted using a modified extraction protocol [@b0120] and, as mentioned previously, processed at the UCLA-DRC laboratory at the INRB. The DBS extraction and assay protocol and multiplex technology have been described elsewhere [@b0125], [@b0130]. Briefly, a 0.25″ DBS punch was extracted, shaking at room temperature, in 1 ml phosphate buffered saline, 0.05% Tween-20, and 5% dried milk, which represents a 1:143 fold dilution assuming 7 µl of serum per punch. The DYNEX Multiplier chemiluminescent automated immunoassay platform with a research use only SmartPLEX assay for measles, mumps, rubella, varicella-zoster virus, and tetanus (MMRVT) (DYNEX Technologies, Chantilly, Virginia) was used to test samples for IgG antibody response (seroprotective level of measles antibody is generally considered to be at least 120 mIU/mL [@b0135]). Polystyrene beads coated separately with antigen to measles, mumps, rubella, varicella-zoster, and tetanus were immobilized within 54-well SmartPLEX assay strips with 10 beads per well and processed using a prototype DYNEX Multiplier® chemiluminescent automated immunoassay instrument. Assay Score (AS) was calculated as a ratio to a five-donor, pooled positive control (PPC) included in each run. The DYNEX chemiluminescent multiplexed immunoassay should be correlated with the plaque reduction neutralization test (PRNT) in order to definitely correlate International Units with AS, but because this was outside the scope of this project, we have reported antibody according to AS. The Limit of Quantitation (LOQ), representing the detection of specific assay response as AS versus PPC, was calculated to be 0.03 AS, and this value, in supplement to maternal report of measles, was used as an additional inclusion criterion for classifying previous measles infection among children with maternally reported history of measles. We utilized the LOQ in conjunction with maternal report in order to decrease misclassification of maternal reports of measles disease, yet avoid missing cases of infants who may have had measles but did not display a robust immune response. This approach, including analyses for internal validation, has been described in previous work [@b0140]. All measles reports in this study are classified as such by utilizing both maternal report and serologic criteria. The cutoff for seroprotection was determined to be 0.14 AS, as determined by validation of the multiplex MMRV serology panel against US-Food and Drug Administration-cleared commercial kits [@b0130]. For purposes of this manuscript, we use the term "seroprotection" to refer to the laboratory cutoff that we are applying to the group under study, while we consider "immunity" to reflect the individual host's competence to resist measles infection.

2.3. Covariate selection {#s0025}
------------------------

A priori confounders such as age and sex were included in descriptive and regression analyses, as well as other potential confounding variables identified in the literature. Because we previously found associations of vaccination status among the most disadvantaged children compared to the rest of the population [@b0145], we dichotomized variables such as stunting status and wealth index in this way in order to detect potential associations with seroprotection. Because seven or more years of maternal education was found by Hobcraft et al. to be protective against child death [@b0150], this was also included. Low parity was found by Hobcraft to be protective of child death, but in order to better capture the potential exposures from siblings to an individual child, we compared firstborn children to all others as a binary covariate. Although breastfeeding has shown protective associations against child death, because the DHS breastfeeding variable identifies children currently breastfeeding, breastfed in the past, or never breastfed, and the first two categories are strongly tied to age, we did not include this variable in regression analyses. Finally, we included an interaction variable of wealth index x residence in regression analyses to account for the DHS wealth index variable utilizing items more frequently found in urban than rural residences to classify wealth [@b0155]. Collinearity diagnostic statistics were performed on all explanatory variables included in the final regression models, with acceptable results (tolerance for all variables was ≥0.75, variance inflation factor for all variables was ≤1.32) for all variables of interest.

2.4. Statistical analyses {#s0030}
-------------------------

Descriptive statistics were performed, and AS geometric mean concentration (GMC) was examined by vaccination report and measles disease history. To assess protectiveness of vaccination and covariates associated with infection, we examined measles cases by age vaccinated (utilizing vaccination report via dated card versus the unvaccinated, n = 2364), year of vaccination (limited to vaccination reports via dated card, n = 738), and nutrition status (stunting) (utilizing the full dataset, n = 6706). We also calculated VE, stratified by age, and limited to vaccination reported via dated card versus the unvaccinated for children 9--59 months of age (n = 2364). Multivariate logistic regression was used to examine both measles infection and seroprotection predicted by vaccination status (limited to vaccinations reported via dated card versus the unvaccinated). To control for variability in probability of selection and interview, DHS stratum, cluster, and individual sampling weights were applied to analyses.

All analyses were performed using SAS software, Version 9.4 (SAS Institute, Cary, NC). Ethical approval was obtained at UCLA Fielding School of Public Health, the Kinshasa School of Public Health and the U.S. Centers for Disease Control and Prevention. As children were younger than the standard age of assent, the parent or guardian of participating children provided consent on the child's behalf.

3. Results {#s0035}
==========

Out of the sample of 6,706 children 6--59 months, 605 (9%) reported a history of measles and 4264 (64%) were seroprotected against measles. Seroprotection varied by vaccination status and report, with 581/738(79%) of children with vaccination report via dated card, 84/113 (74%) of children with vaccination report via marked card, 2738/3896 (70%) of children with vaccination report via maternal recall, and 861/1959 (44%) of unvaccinated children seroprotected (p \< 0.0001, Wald Chi-Square Test). Prevalence of seroprotection varied by child age at the time of interview ([Table 1](#t0005){ref-type="table"}), regardless of whether a child was vaccinated and how vaccination was reported, with older children showing higher proportions seroprotected. While not all children with a history of measles were seroprotected, interestingly, 40% of the unvaccinated with no history of measles were seroprotected. Seroprotection also varied by province, regardless of vaccination status or type of vaccination report. For a number of covariates (residence, wealth index, severe stunting, and maternal education), differences in proportion seroprotected were more pronounced among unvaccinated children or those with dated card vaccination report, while less variation was seen within the groups reporting vaccination via marked card or maternal recall. Breastfeeding status showed differences in seroprotection in all vaccination groups, with currently breastfed children showing a lower proportion seroprotected than children breastfed in the past.Table 1Seroprotection by basic demographics and vaccination status among children 6--59 months.VariableTotalDated cardMarked cardMaternal recallUnvaccinatednSP[1](#tblfn1){ref-type="table-fn"}%nSP%nSP%nSP%*Age (months)*6--8359------1002562433253169--114126135573001236654225693112--23153722916572422867772444584941813724--59439844838185665786297622227590855962p-value[2](#tblfn2){ref-type="table-fn"}**0.0046**--**\<0.0001\<0.0001**  *Age at vaccination*\< 998987273------------9--1153753742980------------≥ 121031038078------------p-value0.6658  *Measles*Yes60537359513131003913288416313583No6101702546789972733505241069179572640p-value**0.00610.0286\<0.0001\<0.0001**  *Sex*Male334835227478594271196513436897241943Female335738630780544380193113957298644245p-value0.67900.32910.05790.536  *Residence*Urban20673382858437246512108467049917936Rural4639400296747660792686189270153468244p-value**0.0230**0.24980.8537**0.0115**  *Wealth index*Poorest14827546612825898225837158225644Poorer1566139104752719708765816653526049Middle1398150122811614887775517140617443Wealthier1258165128782313577705437131511537Wealthiest106720918187191474650480741955528p-value0.05900.20440.3381**0.0045**  *Severe stunting*[3](#tblfn3){ref-type="table-fn"}Yes1616147122833629819696536747924852No5089591459787655722927208571155461440p-value0.17560.47820.0921**0.0028**  *Maternal education*\< 7 years4254367284776749732388165169148067145≥ 7 years245137129780463576150810877255219034p-value0.49590.82360.1573**0.0005**  *Breastfed*[4](#tblfn4){ref-type="table-fn"}Never1461695622100946569361747Past (not current)428345238986615285284521057495255859Current22342681816848296093054659103327527p-value**0.0038**--**\<0.0001\<0.0001**  *Firstborn vs. later born*Firstborn1236190156821916846684987537418048Later born5470548425789468723228224069165968141p-value0.37270.20630.05720.0684  *Province*Kinshasa4721039693536929423479702535Kwango328282172534921512458792734Kwilu5101915789550359236661235242Mai-Ndombe307191052------20815776794253Kongo Central2953926661055318312669631421Equateur20954458422100937884603252Mongala22500000013812389865362Nord-Ubangi10533100------806784221776Sud-Ubangi3221297799100175129741277257Tshuapa1362289------785165562647Kasai222207371----1217562803240Kasai-Central3015733586610013182631074037Kasai-Oriental2722515591375313172551023736Lomami332878322100203132651203832Sankuru12210161050502958712636Haut-Katanga289252494449019111460682130Haut-Lomami15475632----763851692739Lualaba119117695474462145561832Tanganyka1363393------472451863945Maniema22410551------1327959823441Nord-Kivu5451771538611109427423285834656Bas-Uele1476350------1028079402357Haut-Uele9864552273644469261868Ituri18098951514911159583412971Tshopo1555510033100817086663554Sud-Kivu50289778687130922473954143p-value----**\<0.00010.0011**  **Total observations670673811338961959**[^2][^3][^4][^5]

The AS GMC for the entire sample of children aged 6--59 months was 0.159 (SE: 0.006), and stratified GMC varied across age categories within each type of vaccination report, between vaccination report types, and by measles disease report ([Supplementary Table 1](#s0065){ref-type="sec"}). Overall, children with vaccination report via dated card displayed the highest GMC ([Supplementary Table 1A](#s0065){ref-type="sec"}), and all vaccination categories displayed the highest GMC within the oldest age groups. All groups under 12 months of age demonstrated GMC values below the seroprotective range in all applicable vaccination categories. Stratifying by reported measles status ([Supplementary Table 1B](#s0065){ref-type="sec"}), all vaccination categories showed a higher GMC among children with a history of measles than among those with no history of measles.

Measles reports were examined by age at vaccination (children with dated card vaccination reports versus the unvaccinated), year of vaccination (limited to children with dated card vaccination report), and severe stunting (full dataset) ([Table 2](#t0010){ref-type="table"}). Among children vaccinated at less than 9 months of age and 9--11 months of age, 6% and 5%, respectively, had a history of measles, and among those vaccinated at one year of age or older, 2% had a history of measles. Examination of year of vaccination revealed that a higher percentage of children vaccinated in earlier years had a history of measles. Eleven per cent of severely stunted children had a history of measles versus 8% of children who were not severely stunted with a history of measles (p = 0.0259).Table 2Measles cases by age vaccinated, year of vaccination, and severe stunting.Age at time of vaccination (months)[1](#tblfn5){ref-type="table-fn"}Measles −%Measles +%TotalUnvaccinated146490162101626\< 9939566989--1150794295537≥ 121019822103  **Total2166**92**198**82364**p-value**[2](#tblfn6){ref-type="table-fn"}**0.0051**  *Year of vaccination*[3](#tblfn7){ref-type="table-fn"}20091771729242010102911091122011123938613220121779674184201327399412762014101000010  **Total702**95**37**5738  *Severe stunting*[4](#tblfn8){ref-type="table-fn"}Yes143889178111616No46639242685089  **Total6101**91**605**96706**p-value0.0259**[^6][^7][^8][^9]

Vaccination only showed a protective association against measles in the adjusted logistic regression model when vaccination was given at 12 months of age or older ([Table 3](#t0015){ref-type="table"}) (Crude OR: 0.18, 95% CI: 0.03--0.94; Adjusted OR: 0.15, 95% CI: 0.03--0.81), although vaccination was predictive of seroprotection at all ages of vaccination. Firstborn children were also more likely than later born children to be seroprotected (Adjusted OR: 1.51, 95% CI: 1.13--2.03). Limiting vaccination reports to those with dated card ([Table 4](#t0020){ref-type="table"}), VE was low (59%) among children 9--11 months of age, highest (88%) among those 12--24 months, and lowest among the oldest children (43%).Table 3Measles disease and measles protective immunity predicted by vaccination (comparing children with dated card vaccination report versus the unvaccinated, n = 2364). Limited to children 9--59 months of age.VariableCrude odds ratio and 95% CIAdjusted odds ratio[1](#tblfn9){ref-type="table-fn"} and 95% CI*Measles infection outcome***Measles vaccination (ref = unvaccinated)**Vaccination at \<9 months of age0.54 (0.13--2.34)0.80 (0.19--3.30)Vaccination at 9--11 months of age**0.52 (0.28--0.96)**0.79 (0.37--1.71)Vaccination at ≥12 months of age**0.18 (0.03--0.94)0.15 (0.03--0.82)**  **Maternal education**Primary versus no education (ref)**0.55 (0.34**--**0.88)**0.63 (0.36--1.10)  **Birth order**Firstborn versus later born (ref)1.19 (0.79--1.80)1.39 (0.89--2.16)  **Malnutrition**Severe stunting versus all others (ref)**1.50(1.02--2.20)**1.23 (0.85--1.78)  *Seroprotection outcome***Measles vaccination**Vaccination at \<9 months of age**2.81 (1.28--6.17)2.46 (1.13--5.35)**Vaccination at 9--11 months of age**4.03 (2.85--5.68)3.56 (2.40--5.27)**Vaccination at ≥12 months of age**3.42 (1.74--6.73)2.44 (1.10--5.42)**  **Maternal education**Primary versus no education (ref)1.22 (0.94--1.58)0.91 (0.68--1.23)  **Birth order**Firstborn versus later born (ref)**1.52 (1.16--1.98)1.51 (1.13--2.03)**  **Severe stunting**Severe stunting versus all others (ref)1.26 (0.95--1.66)1.26 (0.87--1.82)[^10]Table 4Vaccine effectiveness stratified by age, limited to vaccination reports via dated card versus the unvaccinated (n = 2364).Age (months)No history of measlesHistory of measlesTotal (n)Attack rate (per 100)[1](#tblfn10){ref-type="table-fn"}, [2](#tblfn11){ref-type="table-fn"}Vaccine effectiveness (%)[3](#tblfn12){ref-type="table-fn"}9--11Unvaccinated21692254.059.0Vaccinated601611.6  12--23Unvaccinated458354947.187.7Vaccinated22722290.9  24--59Unvaccinated79111790812.942.8Vaccinated415334487.4  TotalUnvaccinated1464162162610.049.7Vaccinated702377385.0[^11][^12][^13]

4. Discussion {#s0040}
=============

Immunity derived from a single dose of measles vaccine administered at 9 months of age is too low to effectively interrupt measles virus transmission in DRC, with only approximately two-thirds of children demonstrating seroprotection. Previous work suggests that lack of seroprotection could be due to lack of vaccination, failure to mount an effective immune response, loss of vaccine integrity (via breaks in the cold chain or other means), incorrect vaccine administration, vaccination failure, host genetic factors, or infant infection during which maternal antibody interference prevents a robust immune response [@b0070], [@b0160], [@b0165], [@b0170], [@b0175].

Seroconversion GMC did not reach the seroprotective range for the age groups under 12 months, regardless of vaccination status or report type. Children who had been vaccinated at 6--8 months of age and 9--11 months of age demonstrated the highest percentage of measles reports among those reporting vaccination via dated card (6% and 5%, respectively) in our analysis (although most of these reports occurred when the child was nine months of age or older). As stated previously, 6--8 month infants are below the recommended age for the first dose of measles vaccine, yet are at risk of measles infection [@b0180], [@b0185], [@b0190]. In outbreak settings, vaccination is made available to infants 6 months of age and older, however this is a short eligibility period and unlikely to have affected many of the children in the study. Finally, as measles outbreaks are episodic and seasonal, the nationwide outbreaks of 2011--2012 would have infected the 12--24 month cohorts in the 2013--2014 DHS, whereas the infants who were born after the outbreak had a lower risk of measles exposure, which may contribute to the difference in immunity observed between these ages [@b0195]. Further research is warranted to determine the impact of seropositivity due to natural infection or vaccination among infants and to inform recommendations on the timing of the first dose of measles in endemic measles settings such as DRC.

Among children vaccinated from 9--11 months of age, vaccination did not have a protective association against measles in the adjusted logistic regression model. Further, VE at 59% was suboptimal and even below the WHO African Region report of a median VE of 73% [@b0200]. Measles vaccination at 9 months of age is thought to have a 10--15% vaccination failure rate [@b0205], and one U.S. study found a measles attack rate of 6.3% in children vaccinated prior to 12 months of age (attack rate in unvaccinated children was 8.5%, and 1.7% in children vaccinated at ≥12 months of age), with vaccine failure determined to play a meaningful role in this outbreak [@b0080]. Although nine months is the recommended age for the first routine dose of measles vaccine in DRC, a single dose administered at 9 months does not appear to induce adequate protection against measles in our study population.

Children one year of age or older was the only group showing a protective association of vaccination against measles in the adjusted logistic regression model. VE in our analysis was found to be highest among children 12--24 months of age (88%), and this differs somewhat from the Doshi et. al findings, examining measles cases from case-based surveillance in the DRC [@b0045]. Low VE might indicate improper vaccine administration, underreporting of disease, vaccination misclassification, or vaccine failure. Reasons for lower VE in older age groups should be further explored. Additionally, VE may have been affected by children vaccinated via SIAs yet reported as unvaccinated in the DHS, and such misclassification could have driven the VE closer to the null value.

There are a few findings that warrant additional comment. First, 40% of the unvaccinated who did not have measles did have seroprotective measles antibody values ([Table 1](#t0005){ref-type="table"}), suggesting that measles illness could have gone unrecognized (perhaps during the extensive measles outbreaks in 2011--2012), that vaccination due to SIA might have occurred among children classified as unvaccinated by the DHS, or that vaccination cards might have underestimated coverage, as has been found in low-middle and high-income countries [@b0210]. Second, 16% and 17%, respectively, of the maternal recall and unvaccinated groups had a history of measles yet did not have protective levels of measles antibody. This suggests that some reported measles was in fact not measles and perhaps rubella or other viral exanthems. Regarding serologic trends according to breastfeeding status, in general, children breastfed in the past demonstrated a higher percentage of individuals seroprotected versus children currently breastfed. We suggest that this is at least partially explained by age, with children breastfed in the past more likely to be older and vaccinated. Neither wealth index nor the wealth index x residence interaction variable were statistically significant predictors in the regression models.

There was a statistically significant association between severe chronic malnutrition (stunting) and measles (p = 0.0259). Stunting is chronic in nature, and was only measured at the time of the DHS study, while measles occurred in children at various timepoints preceding the study. For this reason, although we cannot say whether severe stunting increased risk of measles, it is a strong indicator of previous poor nutritional status which is associated with the depression of cell-mediated immunity and known to impact susceptibility to infectious diseases in children [@b0055], [@b0060]. While severely malnourished children showed higher prevalence of measles compared to all other children, malnutrition was not a significant predictor in the regression analyses limited to vaccination reports via dated card, and this may have been due to any impact of malnutrition on measles infection being explained by other covariates in the model for this group of children.

Strengths of this study include a large, nationally representative sample and increased confidence in maternal measles reports due to confirmation of measles serology via multiplex assay. To our knowledge, this is the first study to report national measles seroprotection status of children in DRC. Classification of vaccination status and measles history were the core challenges of this study. First, potential residual misclassification of vaccination status, particularly among the maternal recall vaccination reports, was a concern. If misclassification of vaccine status occurred, it was likely differential, since children with vaccination cards were more likely to have correctly classified vaccination status than those who reported via maternal recall. Differential misclassification could result in estimates biased either toward or away from the null. To address this concern, we limited a number of analyses to vaccinations reported via dated card. A second limitation in terms of vaccination classification is our lack of individual-level data for measles SIAs. It is possible that a child may have had an additional dose of measles vaccine that was not reported as part of the DHS. Similarly, we were only able to verify a single dose of measles vaccination through DHS vaccination data, but via SIA, some children may have received a second dose. Thirdly, as discussed in previous work [@b0140], laboratory-confirmed diagnosis of measles was not available, and so we could not fully verify that children classified as having measles did not have measles antibody due to vaccination alone. Although clinical signs of measles can support a higher positive predictive value in measles endemic areas (when laboratory confirmation is not available) [@b0215], measles reports were obtained from mothers rather than trained health care workers, and so may be less reliable. However, other work utilizing household surveys in sub-Saharan Africa has shown that maternal report can be a valid measure for events surrounding child illness [@b0215]. In addition to maternal recall, we were able to substantiate reports of measles with child serologic data, therefore lessening the possibility of outcome misclassification due to maternal recall. Finally, if misclassification of measles status occurred, this might have made the VE estimates appear falsely low, as false positive maternal reports among the unvaccinated might have been excluded for not meeting the IgG criterion of 0.03 AS, but false positive maternal reports among the vaccinated might have been categorized as measles cases by meeting the 0.03 AS criterion due to vaccine-induced antibody.

5. Conclusion {#s0045}
=============

This study identifies clear gaps in measles seroprotection that can inform future policy and research. Our results demonstrate that a single vaccination at 9 months of age (or earlier) is associated with significant vaccination failure contributing to inadequate seroprotection in DRC. Population immunity against measles can be improved by expanding measles vaccination coverage, ensuring that vaccination results in adequate immunity to protect against measles infection, and incorporating a second dose of measles vaccine into the routine vaccination schedule, as recommended by WHO. Understanding factors that decrease host seroprotection and increase risk of vaccine failure will aid in developing more efficient and effective immunization programs.
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[^2]: SP = number of seroprotected individuals.

[^3]: Wald chi-square test. Not performed for subgroups with empty cells.

[^4]: According to National Center for Health Statistics/Centers for Disease Control and Prevention/World Health Organization international references standard for height/age standard deviation.

[^5]: The "breastfed" variable had only 6663 observations.

[^6]: Limited to children with vaccination report via dated card versus the unvaccinated.

[^7]: Wald chi-square test for independence of row and column variables.

[^8]: Limited only to children with vaccination report via dated card.

[^9]: Utilizing the full dataset (all vaccination report types and the unvaccinated).

[^10]: Controlling for the following additional covariates: age, mother\'s education, sex, rural versus urban residence, wealth index, residence \* wealth index interaction, birth order, province of residence, and stunting (according to National Center for Health Statistics/Centers for Disease Control and Prevention/World Health Organization international references standard for height/age standard deviation).

[^11]: Attack rate in the unvaccinated calculated as: (cases among the unvaccinated/total unvaccinated) × 100.

[^12]: Attack rate in the vaccinated calculated as: (cases among the vaccinated/total vaccinated) × 100.

[^13]: Vaccine effectiveness calculated as: ((AR~unvaccinated~ − AR~vaccinated~)/AR~unvaccinated~) × 100.
